<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778426</url>
  </required_header>
  <id_info>
    <org_study_id>1051</org_study_id>
    <nct_id>NCT01778426</nct_id>
  </id_info>
  <brief_title>Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy (French SCS Registry)</brief_title>
  <acronym>SME</acronym>
  <official_title>Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedtronicNeuro</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedtronicNeuro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study to evaluate the long term efficacy of Spinal Cord Stimulation (SCS) over
      2 years following SCS implant.

      This study is requested by French Health Authorities for reimbursement renewal, to maintain
      reimbursement for SCS in approved indication in France.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with predominant pain intensity from baseline to two years follow-up. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With at Least 50% Pain Relief in the Area of Non-predominant Pain</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with non-predominant pain intensity at 1 and 2 years follow-up, compared to baseline. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with predominant pain intensity from baseline to one year follow-up. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant Pain Relief Medication</measure>
    <time_frame>Baseline, 1 and 2 years</time_frame>
    <description>Percentage of primo-implanted subjects taking pain relief medication at baseline, 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose of Analgesics Level 3 (Morphinics)</measure>
    <time_frame>Baseline, 1 and 2 years</time_frame>
    <description>Dose of analgesics level 3 (morphinics) summarized as equivalent morphine dose at baseline, 1 and 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Percentage of primo-implanted subjects satisfied with the treatment 1 and 2 years after implantation (defined as indicating &quot;pain relief improvement,&quot; &quot;daily life improvement,&quot; &quot;rather satisfied with the treatment,&quot; or &quot;would agree to the treatment again&quot;).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Work</measure>
    <time_frame>1 and 2 years</time_frame>
    <description>Percentage of subjects being invalid at inclusion and active at 1 and 2 years.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">414</enrollment>
  <condition>Chronic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Patients with Medtronic neurostimulator</arm_group_label>
    <description>Patients suffering from chronic neuropathic pain syndrome implanted (first implant or replacements) with a Medtronic neurostimulator.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients implanted (first implant or replacements) with a Medtronic neurostimulator in
        selected French sites .
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient indicated for Spinal Cord Stimulation (pain therapy)

          -  Patient implanted for less than 3 months or hospitalized for the implant of a
             Medtronic neurostimulator including:

          -  primary implant with Spinal Cord Stimulation indication and positive test of
             stimulation or

          -  device replacement of a Medtronic neurostimulator used for Pain Therapy

          -  Evaluation of usual pain in the back, upper and lower limbs using a visual analogic
             scale must be available for the 3 days preceding implant.

          -  Treatments must also be available

          -  Patient read and signed the data release form

        Exclusion Criteria:

          -  Patient declined participation

          -  Patient is not available for follow up

          -  Stimulation of other body part than spinal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Christine DJIAN, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Saint Anne, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Foch - 40 rue Worth</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <results_first_submitted>January 12, 2017</results_first_submitted>
  <results_first_submitted_qc>May 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic neuropathic pain syndrome</keyword>
  <keyword>Spinal Cord Stimulation</keyword>
  <keyword>Painstim devices</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject enrolled in the study on January 13, 2012. The last subject was enrolled on December 19, 2013 and the last visit of the last subject was on January 11, 2016. A total of 414 patients were assessed for eligibility, across 28 sites in France, of which, 402 subjects were included in the final analysis.</recruitment_details>
      <pre_assignment_details>Not applicable; this study was non-randomized in which no treatment group was assigned.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Primo-implant (PI)</title>
          <description>Subjects implanted for the first time with Medtronic SCS devices, in order to assess the effectiveness of the treatment compared to pre-operative situation.</description>
        </group>
        <group group_id="P2">
          <title>Replacement (RP)</title>
          <description>Subjects implanted with a new Medtronic SCS neurostimulator as a replacement of their Medtronic SCS devices, in order to document the integrality of the practice and collect long-term data like complications and definitive explants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study - Full Analysis Set (FAS)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="264"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="208"/>
                <participants group_id="P2" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intention-To-Treat (ITT) - Completer</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="0">Not applicable: ITT-completer contains only primo-implant subjects.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="198"/>
                <participants group_id="P2" count="0">Not applicable: ITT-completer contains only primo-implant subjects.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>FAS includes all subjects from primo-implant (n=264) and replacement (n=138) groups enrolled in the study with a valid Patient Data Release Form. 402 subjects were analyzed in the FAS.</population>
      <group_list>
        <group group_id="B1">
          <title>Primo-implant (PI)</title>
          <description>Subjects implanted for the first time (primary implant group) with Medtronic SCS devices, in order to assess the effectiveness of the treatment compared to pre-operative situation.</description>
        </group>
        <group group_id="B2">
          <title>Replacement (RP)</title>
          <description>Subjects implanted with a new Medtronic SCS neurostimulator as a replacement of their Medtronic SCS devices (replacement group), in order to document the integrality of the practice and collect long-term data like complications and definitive explants.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="264"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="402"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="9.6"/>
                    <measurement group_id="B2" value="56.5" spread="11.4"/>
                    <measurement group_id="B3" value="52.0" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 2 Years</title>
        <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with predominant pain intensity from baseline to two years follow-up. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
        <time_frame>2 years</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant (PI)</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 2 Years</title>
          <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with predominant pain intensity from baseline to two years follow-up. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="51.9" upper_limit="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With at Least 50% Pain Relief in the Area of Non-predominant Pain</title>
        <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with non-predominant pain intensity at 1 and 2 years follow-up, compared to baseline. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
        <time_frame>1 year and 2 years</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant (PI)</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 50% Pain Relief in the Area of Non-predominant Pain</title>
          <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with non-predominant pain intensity at 1 and 2 years follow-up, compared to baseline. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="38.3" upper_limit="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="38.3" upper_limit="54.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 1 Year</title>
        <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with predominant pain intensity from baseline to one year follow-up. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
        <time_frame>1 year</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant (PI)</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With at Least 50% Pain Relief in the Area of Predominant Pain at 1 Year</title>
          <description>Percentage of primo-implanted subjects who responded to the treatment, where response was defined as a pain relief of at least 50% in the area with predominant pain intensity from baseline to one year follow-up. Pain intensity was assessed using an 11-point (0-10) Numeric Pain Rating Scale (NPRS) ranging from 0 (no pain) to 10 (maximum pain possible).</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
          <units>Percentage of responders</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="53.1" upper_limit="67.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concomitant Pain Relief Medication</title>
        <description>Percentage of primo-implanted subjects taking pain relief medication at baseline, 1 and 2 years.</description>
        <time_frame>Baseline, 1 and 2 years</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant - Baseline</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Primo-implant - 1 Year</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 1 year follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Primo-implant - 2 Years</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 2 years follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Concomitant Pain Relief Medication</title>
          <description>Percentage of primo-implanted subjects taking pain relief medication at baseline, 1 and 2 years.</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
          <units>Percentage of subject taking drug</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="179"/>
                <count group_id="O3" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Analgesic, level 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" lower_limit="51.9" upper_limit="66.0"/>
                    <measurement group_id="O2" value="43.3" lower_limit="35.9" upper_limit="50.9"/>
                    <measurement group_id="O3" value="43.9" lower_limit="36.9" upper_limit="51.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic, level 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.1" lower_limit="53.9" upper_limit="67.9"/>
                    <measurement group_id="O2" value="35.4" lower_limit="28.4" upper_limit="42.9"/>
                    <measurement group_id="O3" value="36.4" lower_limit="29.7" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesic, level 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" lower_limit="37.9" upper_limit="52.2"/>
                    <measurement group_id="O2" value="19.7" lower_limit="14.1" upper_limit="26.3"/>
                    <measurement group_id="O3" value="18.7" lower_limit="13.5" upper_limit="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSAID</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="22.6" upper_limit="35.6"/>
                    <measurement group_id="O2" value="9.0" lower_limit="5.2" upper_limit="14.2"/>
                    <measurement group_id="O3" value="8.6" lower_limit="5.1" upper_limit="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antiepileptic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.7" lower_limit="62.8" upper_limit="76.0"/>
                    <measurement group_id="O2" value="38.2" lower_limit="31.0" upper_limit="45.8"/>
                    <measurement group_id="O3" value="30.3" lower_limit="24.0" upper_limit="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Antidepressant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" lower_limit="46.8" upper_limit="61.1"/>
                    <measurement group_id="O2" value="33.7" lower_limit="26.8" upper_limit="41.2"/>
                    <measurement group_id="O3" value="29.8" lower_limit="23.5" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dose of Analgesics Level 3 (Morphinics)</title>
        <description>Dose of analgesics level 3 (morphinics) summarized as equivalent morphine dose at baseline, 1 and 2 years.</description>
        <time_frame>Baseline, 1 and 2 years</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.
Here, patients taking analgesics level 3 medications were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant - Baseline</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at baseline.</description>
          </group>
          <group group_id="O2">
            <title>Primo-implant - 1 Year</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 1 year follow-up.</description>
          </group>
          <group group_id="O3">
            <title>Primo-implant - 2 Years</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 2 years follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose of Analgesics Level 3 (Morphinics)</title>
          <description>Dose of analgesics level 3 (morphinics) summarized as equivalent morphine dose at baseline, 1 and 2 years.</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.
Here, patients taking analgesics level 3 medications were considered.</population>
          <units>Daily equivalent morphine dose in mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.2" spread="67.3"/>
                    <measurement group_id="O2" value="102.6" spread="95.8"/>
                    <measurement group_id="O3" value="100.3" spread="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Percentage of primo-implanted subjects satisfied with the treatment 1 and 2 years after implantation (defined as indicating &quot;pain relief improvement,&quot; &quot;daily life improvement,&quot; &quot;rather satisfied with the treatment,&quot; or &quot;would agree to the treatment again&quot;).</description>
        <time_frame>1 and 2 years</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant - 1 Year</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 1 year follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Primo-implant - 2 Years</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 2 years follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Percentage of primo-implanted subjects satisfied with the treatment 1 and 2 years after implantation (defined as indicating &quot;pain relief improvement,&quot; &quot;daily life improvement,&quot; &quot;rather satisfied with the treatment,&quot; or &quot;would agree to the treatment again&quot;).</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
          <units>Percentage of subjects satisfied</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain relief improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="84.5" upper_limit="93.9"/>
                    <measurement group_id="O2" value="89.3" lower_limit="84.2" upper_limit="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>daily life activity improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" lower_limit="75.6" upper_limit="87.4"/>
                    <measurement group_id="O2" value="81.8" lower_limit="75.7" upper_limit="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>treatment satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.9" lower_limit="84.5" upper_limit="93.9"/>
                    <measurement group_id="O2" value="91.4" lower_limit="86.6" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>agree to the treatment again</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" lower_limit="87.2" upper_limit="95.6"/>
                    <measurement group_id="O2" value="92.9" lower_limit="88.4" upper_limit="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Return to Work</title>
        <description>Percentage of subjects being invalid at inclusion and active at 1 and 2 years.</description>
        <time_frame>1 and 2 years</time_frame>
        <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Primo-implant - 1 Year</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 1 year follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Primo-implant - 2 Years</title>
            <description>Subjects implanted for the first time with Medtronic SCS devices. Results at 2 years follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Return to Work</title>
          <description>Percentage of subjects being invalid at inclusion and active at 1 and 2 years.</description>
          <population>ITT – completer (n=198) consists of all primo-implant subjects with baseline and follow-up pain intensity data at 2 years completed. Among 198 subjects, 179 patients had a visit at one year completed.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from enrollment through the study end.</time_frame>
      <desc>Adverse events related to the device or procedure (including definitive explant or repositioning) were collected. Whether an event met the criteria of serious was determined by the study site.</desc>
      <group_list>
        <group group_id="E1">
          <title>Full Analysis Set (FAS)</title>
          <description>FAS includes all subjects from primo-implant (n=264) and replacement (n=138) groups enrolled in the study with a valid Patient Data Release Form. 402 subjects were analyzed in the FAS.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device end of service</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device extension damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device lead damage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device lead issue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device stimulation issue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Implant site hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Implant site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Medical device discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Medical device site pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Surgical skin tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Wound complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Allodynia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Phantom pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device ineffective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Device stimulation issue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Implant site discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Implant site hematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Implant site pain</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Lead dislodgement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Medical device discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Therapeutic product ineffective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Meningocele acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Neurostimulator removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Subcutaneous hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="402"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>It is stated in the CIP and Agreement signed by the investigators that the French SCS Registry data are the sole property of Medtronic.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The targeted pain area of the therapy was assumed to be the one with the predominant NPRS score at baseline. For the replacement group it was unknown if the therapy was active at the time of the device replacement (enrollment).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Neuromodulation, Clinical Study Management</name_or_title>
      <organization>Medtronic</organization>
      <email>medtronicneurotrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

